CG Oncology (CGON) Gross Margin (2024 - 2026)
CG Oncology posted quarterly Gross Margin of 173.5% for Q1 2026, down 27350.0% year-on-year from N/an in Q1 2025, and down 438.59% on a QoQ basis from 32.21% in Q4 2025.
CG Oncology (CGON) has 3 years of Gross Margin data on file, last reported at 173.5% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 27350.0% year-over-year to 173.5%; the trailing twelve-month figure through Mar 2026 stood at 49.02% (changed N/A YoY), and the FY2025 full-year result was 15.02%, down 11502.0% from the prior year.
- Gross Margin for Q1 2026 stood at 173.5%, down from 32.21% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q3 2024 and bottomed at 173.5% in Q1 2026.
- The 3-year median for Gross Margin is 52.67% (2024), against an average of 16.6%.
- The widest annual swing landed in 2025, when Gross Margin sank 9466 bps; it then sank 27350 bps in 2026.
- A 3-year view of Gross Margin shows it stood at 100.0% in 2024, then sank by 132 bps to 32.21% in 2025, then tumbled by 439 bps to 173.5% in 2026.
- The last three Gross Margin figures came in at 173.5% (Q1 2026), 32.21% (Q4 2025), and 5.34% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | -173.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -173.50% |
| Dec 31, 2025 | -32.21% |
| Sep 30, 2025 | 5.34% |
| Mar 31, 2025 | 100.00% |
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 100.00% |